在一名已服用吡非尼酮的慢性纤维化间质性肺病患者中，尼达尼布引起的光敏性皮炎。 - Suppr

Suppr

超能文献

Photosensitive dermatitis caused by nintedanib in a patient of chronic fibrosing interstitial lung disease already on pirfenidone.

作者信息

Goyal Aurelia, Gupta Sharang, Chopra Dimple

机构信息

Department of Dermatology, Government Medical College, Patiala, Punjab, India.

出版信息

Indian J Pharmacol. 2024 Sep 1;56(5):367-368. doi: 10.4103/ijp.ijp_371_24. Epub 2024 Dec 16.

DOI:10.4103/ijp.ijp_371_24

PMID:39687964

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11698289/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c5a/11698289/e41b154d5183/IJPharm-56-367-g001.jpg

相似文献

Photosensitive dermatitis caused by nintedanib in a patient of chronic fibrosing interstitial lung disease already on pirfenidone.在一名已服用吡非尼酮的慢性纤维化间质性肺病患者中，尼达尼布引起的光敏性皮炎。

Indian J Pharmacol. 2024 Sep 1;56(5):367-368. doi: 10.4103/ijp.ijp_371_24. Epub 2024 Dec 16.

Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases.吡非尼酮和尼达尼布治疗间质性肺疾病的文献计量分析

Heliyon. 2024 Apr 15;10(8):e29266. doi: 10.1016/j.heliyon.2024.e29266. eCollection 2024 Apr 30.

Management of patients with fibrosing interstitial lung diseases.纤维化间质性肺疾病患者的管理。

Am J Health Syst Pharm. 2022 Jan 24;79(3):129-139. doi: 10.1093/ajhp/zxab375.

The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting.在现实生活中，尼达尼布和吡非尼酮对特发性肺纤维化患者肺功能及生存的影响。

Pulm Pharmacol Ther. 2023 Dec;83:102261. doi: 10.1016/j.pupt.2023.102261. Epub 2023 Sep 25.

Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective.进行性纤维化间质性肺疾病：当前观点

Biomedicines. 2021 Sep 16;9(9):1237. doi: 10.3390/biomedicines9091237.

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.可能对进展性肺纤维化非特发性肺纤维化间质性肺疾病患者有抗纤维化药物的价值。

BMC Pulm Med. 2019 Nov 12;19(1):213. doi: 10.1186/s12890-019-0937-0.

Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows.吡非尼酮和尼达尼布治疗肺纤维化：利弊分析

Pharmaceuticals (Basel). 2024 May 30;17(6):709. doi: 10.3390/ph17060709.

Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.尼达尼布治疗慢性纤维化间质性肺疾病患者的暴露-疗效分析。

Respir Med. 2021 Apr-May;180:106369. doi: 10.1016/j.rmed.2021.106369. Epub 2021 Mar 14.

Experimental study of the effects of pirfenidone and nintedanib on joint inflammation and pulmonary fibrosis in a rheumatoid arthritis-associated interstitial lung disease mouse model.吡非尼酮和尼达尼布对类风湿关节炎相关间质性肺疾病小鼠模型关节炎症和肺纤维化影响的实验研究

J Thorac Dis. 2024 Nov 30;16(11):7458-7476. doi: 10.21037/jtd-24-882. Epub 2024 Nov 29.

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.尼达尼布：在纤维化间质性肺疾病中的研究进展。

Drugs. 2021 Apr;81(5):575-586. doi: 10.1007/s40265-021-01487-0. Epub 2021 Mar 25.

本文引用的文献

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic.在新冠疫情期间，尼达尼布与吡非尼酮在特发性肺纤维化患者中的药物相互作用

Pharmaceuticals (Basel). 2021 Aug 20;14(8):819. doi: 10.3390/ph14080819.

Pirfenidone-Induced Photosensitive Dermatitis: A Rare Side Effect.吡非尼酮诱导的光敏性皮炎：一种罕见的副作用。

Cureus. 2021 May 23;13(5):e15200. doi: 10.7759/cureus.15200.

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.尼达尼布联合吡非尼酮治疗特发性肺纤维化的安全性。

Eur Respir J. 2018 Aug 2;52(2). doi: 10.1183/13993003.00230-2018. Print 2018 Aug.

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.尼达尼布联合吡非尼酮治疗特发性肺纤维化：INJOURNEY 试验结果。

Am J Respir Crit Care Med. 2018 Feb 1;197(3):356-363. doi: 10.1164/rccm.201706-1301OC.

Update on photodermatoses.光皮肤病学的最新进展。

Semin Cutan Med Surg. 2011 Dec;30(4):229-38. doi: 10.1016/j.sder.2011.07.007.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验